A compelling body of non-randomized evidence has established stereotactic ablative lung radiotherapy (SABR) as a standard of care for medically inoperable patients with peripheral early-stage non-small cell lung cancer (NSCLC). This convenient outpatient therapy, which is typically delivered in 3-8 fractions, is also well tolerated by elderly and frail patients, makes efficient use of resources and is feasible using standard commercial equipment. The introduction of lung SABR into large populations has led to an increased utilization of radiotherapy, a reduction in the proportion of untreated patients and an increase in overall survival. In selected patients, the same ablative technology can now achieve durable local control of NSCLC metastases in a variety of common locations including the adrenal glands, bone, brain, and liver. At the same time as this, advances in prognostic molecular markers and targeted systemic therapies mean that there is now a subgroup of patients with stage IV NSCLC and a median survival of around 2 years. This creates opportunities for new trials that incorporate SABR and patient-specific systemic strategies. This selective mini-review focuses on the emerging role of SABR in patients with early-stage and oligometastatic NSCLC.
Citations
Citations to this article as recorded by
Navigating patient journey in early diagnosis of lung cancer in India Bivas Biswas, Deepak Talwar, Priti Meshram, Pramod K. Julka, Anurag Mehta, SP Somashekhar, Srinivas Chilukuri, Abhishek Bansal Lung India.2023; 40(1): 48. CrossRef
Design, Synthesis and Anticancer Evaluation of Nitroimidazole Radiosensitisers Lydia P. Liew, Avik Shome, Way W. Wong, Cho R. Hong, Kevin O. Hicks, Stephen M. F. Jamieson, Michael P. Hay Molecules.2023; 28(11): 4457. CrossRef
Breast Metastasis of Lung Cancer After Computed Tomography-Guided Core Needle Biopsy: A Case Report Rong Zhao, Jun Xing, Jinnan Gao Frontiers in Surgery.2022;[Epub] CrossRef
Radiosurgery and fractionated stereotactic radiotherapy in oligometastatic/oligoprogressive non-small cell lung cancer patients: Results of a multi-institutional series of 198 patients treated with “curative” intent Michela Buglione, Barbara Alicja Jereczek-Fossa, Marco Lorenzo Bonù, Davide Franceschini, Andrei Fodor, Isa Bossi Zanetti, Marianna Alessandra Gerardi, Paolo Borghetti, Davide Tomasini, Nadia Gisella Di Muzio, Olga Oneta, Marta Scorsetti, Ciro Franzese, P Lung Cancer.2020; 141: 1. CrossRef
Staging Lung Cancer Girish S. Shroff, Chitra Viswanathan, Brett W. Carter, Marcelo F. Benveniste, Mylene T. Truong, Bradley S. Sabloff Radiologic Clinics of North America.2018; 56(3): 411. CrossRef
Stereotactic Body Radiation Therapy for Early-Stage Non–Small Cell Lung Cancer: A Primer for Radiologists Jennifer A. Febbo, Ramya S. Gaddikeri, Palmi N. Shah RadioGraphics.2018; 38(5): 1312. CrossRef
Preliminary comparison of the registration effect of 4D-CBCT and 3D-CBCT in image-guided radiotherapy of Stage IA non–small-cell lung cancer Zhibo Tan, Chuanyao Liu, Ying Zhou, Weixi Shen Journal of Radiation Research.2017; 58(6): 854. CrossRef
Narcissus, the Beam, and lung cancer Gaetano Rocco The Journal of Thoracic and Cardiovascular Surgery.2016; 152(2): 338. CrossRef
Efficacy of stereotactic radiotherapy for brain metastases using dynamic jaws technology in the helical tomotherapy system Taro Murai, Akihiro Hayashi, Yoshihiko Manabe, Chikao Sugie, Taiki Takaoka, Takeshi Yanagi, Tetsuya Oguri, Masayuki Matsuo, Yoshimasa Mori, Yuta Shibamoto The British Journal of Radiology.2016; 89(1066): 20160374. CrossRef
Targeting tumour hypoxia to prevent cancer metastasis. From biology, biosensing and technology to drug development: the METOXIA consortium Erik O. Pettersen, Peter Ebbesen, Roben G. Gieling, Kaye J. Williams, Ludwig Dubois, Philippe Lambin, Carol Ward, James Meehan, Ian H. Kunkler, Simon P. Langdon, Anne H. Ree, Kjersti Flatmark, Heidi Lyng, Maria J. Calzada, Luis del Peso, Manuel O. Landazu Journal of Enzyme Inhibition and Medicinal Chemistry.2015; 30(5): 689. CrossRef
Monte Carlo validation of the TrueBeam 10XFFF phase–space files for applications in lung SABR Tony Teke, Cheryl Duzenli, Alanah Bergman, Francis Viel, Parmveer Atwal, Ermias Gete Medical Physics.2015; 42(12): 6863. CrossRef
Stratégies d’évaluation de la réponse après irradiation stéréotaxique des cancers bronchiques primitifs et des métastases pulmonaires I. Barillot, O. Munier, M. Hatime, F. Mornex Cancer/Radiothérapie.2014; 18(4): 308. CrossRef
Short-Course Treatment With Gefitinib Enhances Curative Potential of Radiation Therapy in a Mouse Model of Human Non-Small Cell Lung Cancer Sivan M. Bokobza, Yanyan Jiang, Anika M. Weber, Aoife M. Devery, Anderson J. Ryan International Journal of Radiation Oncology*Biology*Physics.2014; 88(4): 947. CrossRef
Can an alternative backround-corrected [18F] fluorodeoxyglucose (FDG) standard uptake value (SUV) be used for monitoring tumor local control following lung cancer stereotactic body radiosurgery? Charles Shang, Michael Kasper, Vindu Kathriarachchi, Rashmi Benda, Joseph Kleinman, Jeremy Cole, Timothy Williams International Journal of Cancer Therapy and Oncology.2014; 2(3): 020317. CrossRef
Stereotactic ablative body radiotherapy combined with immunotherapy: Present status and future perspectives N.H. Rekers, E.G.C. Troost, C.M.L. Zegers, W.T.V. Germeraad, L.J. Dubois, P. Lambin Cancer/Radiothérapie.2014; 18(5-6): 391. CrossRef
Cáncer de pulmón P. Resano Barrio, Y. Anta Mejía Medicine - Programa de Formación Médica Continuada Acreditado.2014; 11(67): 3983. CrossRef
Increasing Use of Advanced Radiation Therapy Technologies in the Last 30 Days of Life Among Patients Dying As a Result of Cancer in the United States B. Ashleigh Guadagnolo, Kai-Ping Liao, Sharon H. Giordano, Linda S. Elting, Thomas A. Buchholz, Ya-Chen Tina Shih Journal of Oncology Practice.2014; 10(4): e269. CrossRef
Extra-thoracic tumor burden but not thoracic tumor burden on 18F-FDG PET/CT is an independent prognostic biomarker for extensive-disease small cell lung cancer Jong-Ryool Oh, Ji-Hyoung Seo, Chae Moon Hong, Shin Young Jeong, Sang-Woo Lee, Jaetae Lee, Jung-Joon Min, Ho-Chun Song, Hee-Seung Bom, Young-Chul Kim, Byeong-Cheol Ahn Lung Cancer.2013; 81(2): 218. CrossRef
Changing trends in radiation therapy technologies in the last year of life for patients diagnosed with metastatic cancer in the United States B. Ashleigh Guadagnolo, Jinhai Huo, Kai‐Ping Liao, Thomas A. Buchholz, Prajnan Das Cancer.2013; 119(5): 1089. CrossRef
Escaping death to quiescence: Avoiding mitotic catastrophe after DNA damage Zhiyuan Shen, Steven C. Huhn, Bruce G. Haffty Cell Cycle.2013; 12(11): 1664. CrossRef
CyberKnife robotic image-guided stereotactic radiotherapy for oligometastic cancer B.A. Jereczek-Fossa, I. Bossi-Zanetti, R. Mauro, G. Beltramo, L. Fariselli, L.C. Bianchi, C. Fodor, P. Fossati, G. Baroni, R. Orecchia Strahlentherapie und Onkologie.2013; 189(6): 448. CrossRef
The development of stereotactic body radiotherapy (SBRT) for medically inoperable early stage non-small cell lung cancer: an international phenomenon Gregory M. M. Videtic Journal of Radiation Oncology.2012; 1(1): 3. CrossRef
Improving lung cancer survival; time to move on Marlies E Heuvers, Joost P Hegmans, Bruno H Stricker, Joachim G Aerts BMC Pulmonary Medicine.2012;[Epub] CrossRef
Radiographic changes after lung stereotactic ablative radiotherapy (SABR) – Can we distinguish recurrence from fibrosis? A systematic review of the literature Kitty Huang, Max Dahele, Suresh Senan, Matthias Guckenberger, George B. Rodrigues, Aaron Ward, R. Gabriel Boldt, David A. Palma Radiotherapy and Oncology.2012; 102(3): 335. CrossRef
PURPOSE The National Cancer Screening Program (NCSP) began in 1999. The objective of this report is to evaluate the results of the NCSP in 2008 and provide essential evidence associated with the gastric cancer screening program in Korea. MATERIALS AND METHODS Data was obtained from the National Cancer Screening Information System; participation rates in gastric cancer screening were calculated. According to screening modalities, recall rates were estimated with 95% confidence intervals (CIs). RESULTS The target population of the gastric cancer screening program in 2008 was 7,132,820 Korean men and women aged 40 and over, 2,076,544 of whom underwent upper endoscopy or upper gastrointestinal (UGI) series as screening tools (participation rate, 29.1%). Disparities in participation rates were observed relating to gender and health insurance type. Overall, recall rates of upper endoscopy and UGI series were 3.1% (95% CI, 3.0 to 3.1) and 33.3% (95% CI, 33.3 to 33.4), respectively. CONCLUSION According to our research, efforts to facilitate participation and to reduce disparities in gastric cancer screening among Korean men and women are needed. These results will provide essential data for evidence-based strategies in gastric cancer control in Korea.
Citations
Citations to this article as recorded by
Global burden, risk factors, clinicopathological characteristics, molecular biomarkers and outcomes of microsatellite instability-high gastric cancer Zhishan Zhang, Jinyuan Huang, Yingying Li, Huimeng Yan, Junxing Xie, Jing Wang, Bin Zhao Aging.2024;[Epub] CrossRef
Endoscopic Submucosal Dissection in the Stomach and Duodenum Sarah S. Al Ghamdi, Saowanee Ngamruengphong Gastrointestinal Endoscopy Clinics of North America.2023; 33(1): 67. CrossRef
A Global Perspective on Gastric Cancer Screening: Which Concepts Are Feasible, and When? Wladyslaw Januszewicz, Maryla Helena Turkot, Peter Malfertheiner, Jaroslaw Regula Cancers.2023; 15(3): 664. CrossRef
Determination of an Appropriate Endoscopic Monitoring Interval for Patients with Gastric Precancerous Conditions in China Kai Zhao, Li-na Feng, Su-hong Xia, Wang-dong Zhou, Ming-yu Zhang, Yu Zhang, Ruo-nan Dong, De-an Tian, Mei Liu, Jia-zhi Liao Current Medical Science.2023; 43(2): 268. CrossRef
How to Improve the Efficacy of Gastric Cancer Screening? Wladyslaw Januszewicz, Maryla Helena Turkot, Jaroslaw Regula Current Treatment Options in Gastroenterology.2023; 21(3): 241. CrossRef
Role of geographic characteristics in the spatial cluster detection of cancer: Evidence in South Korea, 1999–2013 Insang Song, Eun-Hye Yoo, Inkyung Jung, Jin-Kyoung Oh, Sun-Young Kim Environmental Research.2023; 236: 116841. CrossRef
Triplet Chemotherapy with Cisplatin versus Oxaliplatin in the CRITICS Trial: Treatment Compliance, Toxicity, Outcomes and Quality of Life in Patients with Resectable Gastric Cancer Astrid E. Slagter, Irene A. Caspers, Nicole C. T. van Grieken, Iris Walraven, Pehr Lind, Elma Meershoek-Klein Kranenbarg, Cecile Grootscholten, Marianne Nordsmark, Johanna W. van Sandick, Karolina Sikorska, Cornelis J. H. van de Velde, Edwin P. M. Jansen, Cancers.2022; 14(12): 2963. CrossRef
Chinese and Global Burdens of Gastrointestinal Cancers From 1990 to 2019 Wangcheng Xie, Tingsong Yang, Jieliang Zuo, Zhilong Ma, Weidi Yu, Zhengyu Hu, Zhenshun Song Frontiers in Public Health.2022;[Epub] CrossRef
Pathological and oncological outcomes of pylorus-preserving versus conventional distal gastrectomy in early gastric cancer: a systematic review and meta-analysis Sen Hou, Fan Liu, Zhidong Gao, Yingjiang Ye World Journal of Surgical Oncology.2022;[Epub] CrossRef
Disparate and Alarming Impact of Gastrointestinal Cancers in Young Adult Patients Amir Khan, Philip H. G. Ituarte, Mustafa Raoof, Laleh Melstrom, Haiqing Li, Yate-Ching Yuan, Lily Lai, I. Benjamin Paz, Ajay Goel, Yuman Fong, Yanghee Woo Annals of Surgical Oncology.2021; 28(2): 785. CrossRef
Implementation effect of institutional policy of EGD observation time on neoplasm detection Jae Myung Park, Sang Yoon Kim, Ga-Yeong Shin, Younghee Choe, Hyun Sun Cho, Chul-Hyun Lim, Yu Kyung Cho, Myung-Gyu Choi Gastrointestinal Endoscopy.2021; 93(5): 1152. CrossRef
Periodic Fluctuations in the Incidence of Gastrointestinal Cancer Mun-Gan Rhyu, Jung-Hwan Oh, Tae Ho Kim, Joon-Sung Kim, Young A Rhyu, Seung-Jin Hong Frontiers in Oncology.2021;[Epub] CrossRef
Disparities in gastric cancer screening among people with disabilities: a national registry-linkage study in South Korea YoungJee Kim, Dong Wook Shin, Hyoung Woo Kim, Jin Hyung Jung, Kyungdo Han, In Young Cho, So Young Kim, Kui Son Choi, Jong Heon Park, Jong Hyock Park, Ichiro Kawachi Gastric Cancer.2020; 23(3): 497. CrossRef
Analysis of lymph node metastasis in early gastric cancer: a single institutional experience from China Jinggui Chen, Guangfa Zhao, Yanong Wang World Journal of Surgical Oncology.2020;[Epub] CrossRef
Is gastric cancer becoming a rare disease? A global assessment of predicted incidence trends to 2035 Melina Arnold, Jin Young Park, M Constanza Camargo, Nuno Lunet, David Forman, Isabelle Soerjomataram Gut.2020; 69(5): 823. CrossRef
Surveillance Endoscopy Guidelines for Postgastrectomy Patients Based on Risk of Developing Remnant Gastric Cancer Eui Soo Han, Ho Seok Seo, Ji Hyun Kim, Han Hong Lee Annals of Surgical Oncology.2020; 27(11): 4216. CrossRef
Global burden of oesophageal and gastric cancer by histology and subsite in 2018 Melina Arnold, Jacques Ferlay, Mark I van Berge Henegouwen, Isabelle Soerjomataram Gut.2020; 69(9): 1564. CrossRef
Towards Personalization in the Curative Treatment of Gastric Cancer Astrid E. Slagter, Marieke A. Vollebergh, Edwin P. M. Jansen, Johanna W. van Sandick, Annemieke Cats, Nicole C. T. van Grieken, Marcel Verheij Frontiers in Oncology.2020;[Epub] CrossRef
Community-Based Pilot Study of a Screening Program for Gastric Cancer in a Chinese Population Lin Ji, Zengchao Liu, Bin Zhou, Ying Cai, Fangmei An, Lei Wang, Zhifa Lv, Min Xia, Jianbo Yang, Jianfen Yuan, Hui Wang, Zhiyi Zhou, Shudong Yang, Lei Hu, Qiang Zhan Cancer Prevention Research.2020; 13(1): 73. CrossRef
The incidence of lymph node metastasis in submucosal early gastric cancer according to the expanded criteria: a systematic review Mohamed M. Abdelfatah, Mohamed Barakat, Mohamed O. Othman, Ian S. Grimm, Noriya Uedo Surgical Endoscopy.2019; 33(1): 26. CrossRef
Efficacy and safety of endoscopic submucosal dissection for gastric epithelial neoplasia in elderly patients aged 80 years and older Young Woong Son, Ain Kim, Han Ho Jeon Aging Clinical and Experimental Research.2019; 31(12): 1833. CrossRef
Quality of Life in Vietnamese Gastric Cancer Patients Dzung Ngoc Thi Dang, Lan Ngoc Thi Nguyen, Nga Thi Dang, Huy Quang Dang, Thanh Van Ta BioMed Research International.2019; 2019: 1. CrossRef
The incidence of lymph node metastasis in early gastric cancer according to the expanded criteria in comparison with the absolute criteria of the Japanese Gastric Cancer Association: a systematic review of the literature and meta-analysis Mohamed M. Abdelfatah, Mohamed Barakat, Hyuk Lee, Jae J. Kim, Noriya Uedo, Ian Grimm, Mohamed O. Othman Gastrointestinal Endoscopy.2018; 87(2): 338. CrossRef
Aplicación de la endoscopia sistemática alfanumérica codificada más cromoendoscopia para la detección de lesiones precancerosas gástricas y cáncer gástrico temprano en sujetos con riesgo promedio de cáncer gástrico A. Pérez-Mendoza, Á.M. Zárate-Guzmán, E.S. Galvis García, S. Sobrino Cossío, J. Djamus Birch Revista de Gastroenterología de México.2018; 83(2): 117. CrossRef
Non‐alcoholic fatty liver disease and the development of reflux esophagitis: A cohort study Yang Won Min, Youngha Kim, Geum‐Youn Gwak, Seonhye Gu, Danbee Kang, Soo Jin Cho, Eliseo Guallar, Juhee Cho, Dong Hyun Sinn Journal of Gastroenterology and Hepatology.2018; 33(5): 1053. CrossRef
Endoscopic Treatment for Esophageal Cancer Yang Won Min The Korean Journal of Gastroenterology.2018; 71(3): 116. CrossRef
The Effect ofHelicobacter pyloriInfection on the Recurrence of Gastric Hyperplastic Polyp Su Youn Nam The Korean Journal of Gastroenterology.2018; 71(4): 183. CrossRef
Effect of Helicobacter pylori eradication on the regression of gastric polyps in National Cancer Screening Program Su Youn Nam, Bum Joon Park, Kum Hei Ryu, Ji Hyung Nam The Korean Journal of Internal Medicine.2018; 33(3): 506. CrossRef
Endoscopic submucosal dissection under general anesthesia for superficial esophageal squamous cell carcinoma is associated with better clinical outcomes Byeong Geun Song, Yang Won Min, Ra Ri Cha, Hyuk Lee, Byung-Hoon Min, Jun Haeng Lee, Poong-Lyul Rhee, Jae J. Kim BMC Gastroenterology.2018;[Epub] CrossRef
Systematic alphanumeric-coded endoscopy versus chromoendoscopy for the detection of precancerous gastric lesions and early gastric cancer in subjects at average risk for gastric cancer A. Pérez-Mendoza, Á.M. Zárate-Guzmán, E.S. Galvis García, S. Sobrino Cossío, J. Djamus Birch Revista de Gastroenterología de México (English Edition).2018; 83(2): 117. CrossRef
Occurrence of gastric cancer in patients with atrophic gastritis during long-term follow-up Liming Zhang, Yulan Liu, Peng You, Guijian Feng Scandinavian Journal of Gastroenterology.2018; 53(7): 843. CrossRef
Comparison of endoscopic submucosal dissection and surgery for superficial esophageal squamous cell carcinoma: a propensity score-matched analysis Yang Won Min, Hyuk Lee, Byeong Geun Song, Byung-Hoon Min, Hong Kwan Kim, Yong Soo Choi, Jun Haeng Lee, Na-Young Hwang, Keumhee C. Carriere, Poong-Lyul Rhee, Jae J. Kim, Jae Ill Zo, Young Mog Shim Gastrointestinal Endoscopy.2018; 88(4): 624. CrossRef
Discovery and Validation of Salivary Extracellular RNA Biomarkers for Noninvasive Detection of Gastric Cancer Feng Li, Janice M Yoshizawa, Kyoung-Mee Kim, Julie Kanjanapangka, Tristan R Grogan, Xiaoyan Wang, David E Elashoff, Shigeo Ishikawa, David Chia, Wei Liao, David Akin, Xinmin Yan, Min-Sun Lee, Rayun Choi, Su-Mi Kim, So-Young Kang, Jae-Moon Bae, Tae-Sung So Clinical Chemistry.2018; 64(10): 1513. CrossRef
Endoscopic prediction model for differentiating upper submucosal invasion (< 200 μm) and beyond in superficial esophageal squamous cell carcinoma Joohwan Bae, In Seub Shin, Yang Won Min, Insuk Sohn, Joong Hyun Ahn, Hyuk Lee, Byung-Hoon Min, Jun Haeng Lee, Poong-Lyul Rhee, Jae J. Kim Oncotarget.2018; 9(10): 9156. CrossRef
Differences in upper gastrointestinal neoplasm detection rates based on inspection time and esophagogastroduodenoscopy training Shoichi Yoshimizu, Toshiaki Hirasawa, Yusuke Horiuchi, Masami Omae, Akiyoshi Ishiyama, Toshiyuki Yoshio, Tomohiro Tsuchida, Junko Fujisaki Endoscopy International Open.2018; 06(10): E1190. CrossRef
Endoscopic Management of Early Gastric Adenocarcinoma and Preinvasive Gastric Lesions Saowanee Ngamruengphong, Seiichiro Abe, Ichiro Oda Surgical Clinics of North America.2017; 97(2): 371. CrossRef
Effectiveness of the Korean National Cancer Screening Program in Reducing Gastric Cancer Mortality Jae Kwan Jun, Kui Son Choi, Hoo-Yeon Lee, Mina Suh, Boyoung Park, Seung Hoon Song, Kyu Won Jung, Chan Wha Lee, Il Ju Choi, Eun-Cheol Park, Dukhyoung Lee Gastroenterology.2017; 152(6): 1319. CrossRef
Evaluation of Transabdominal Ultrasound with Oral Cellulose-Based Contrast Agent in the Detection and Surveillance of Gastric Ulcer Zhijun Liu, Jintao Guo, Shupeng Wang, Ying Zhao, Zhining Liu, Jing Li, Weidong Ren, Shaoshan Tang, Limei Xie, Ying Huang, Siyu Sun, Liping Huang Ultrasound in Medicine & Biology.2017; 43(7): 1364. CrossRef
Longer Observation Time Increases Proportion of Neoplasms Detected by Esophagogastroduodenoscopy Jae Myung Park, Sol Mi Huo, Han Hee Lee, Bo-In Lee, Ho Jin Song, Myung-Gyu Choi Gastroenterology.2017; 153(2): 460. CrossRef
Risk Factors for Gastric Tumorigenesis in Underlying Gastric Mucosal Atrophy Ji Hyun Song, Sang Gyun Kim, Eun Hyo Jin, Joo Hyun Lim, Sun Young Yang Gut and Liver.2017; 11(5): 612. CrossRef
Belching during gastroscopy and its association with gastroesophageal reflux disease B. S. Lee, S. H. Lee, D. K. Jang, K. H. Chung, J. H. Hwang, S. E. Jang, B. H. Cha, J. K. Ryu, Y.-T. Kim Diseases of the Esophagus.2016; 29(4): 342. CrossRef
Endoscopic and oncologic outcomes according to indication criteria of endoscopic resection for early gastric cancer: a systematic review and meta-analysis Se Woo Park, Hyuk Lee, Chan Hyuk Park, Hyun Joo Jang, Hongyup Ahn Surgical Endoscopy.2016; 30(4): 1270. CrossRef
The risk of lymph node metastases in 3951 surgically resected mucosal gastric cancers: implications for endoscopic resection Kang Kook Choi, Jae Moon Bae, Su Mi Kim, Tae Sung Sohn, Jae Hyung Noh, Jun Ho Lee, Min-Gew Choi, Sung Kim Gastrointestinal Endoscopy.2016; 83(5): 896. CrossRef
The Influence of Gastric Cancer Screening on the Stage at Diagnosis and Survival Esha Khanderia, Sheraz R. Markar, Amish Acharya, Yeol Kim, Young-Woo Kim, George B. Hanna Journal of Clinical Gastroenterology.2016; 50(3): 190. CrossRef
Differences in routine esophagogastroduodenoscopy between Japanese and international facilities: A questionnaire survey Noriya Uedo, Takuji Gotoda, Shigetaka Yoshinaga, Tokuma Tanuma, Yoshinori Morita, Hisashi Doyama, Akira Aso, Toshiaki Hirasawa, Tomonori Yano, Norihisa Uchita, Shiaw‐Hooi Ho, Ping‐Hsin Hsieh Digestive Endoscopy.2016; 28(S1): 16. CrossRef
Current Perspectives on Gastric Cancer Juan M. Marqués-Lespier, María González-Pons, Marcia Cruz-Correa Gastroenterology Clinics of North America.2016; 45(3): 413. CrossRef
Meta‐analysis of confocal laser endomicroscopy for the diagnosis of gastric neoplasia and adenocarcinoma Wei Qian, Tao Bai, Huan Wang, Lei Zhang, Jun Song, Xiao Hua Hou Journal of Digestive Diseases.2016; 17(6): 366. CrossRef
Endoscopic Submucosal Dissection Outcomes for Gastroesophageal Tumors in Low Volume Units: A Multicenter Survey Ahmad Najib Azmi, Christopher J. L. Khor, Khek-Yu Ho, Rapat Pittayanon, Rungsun Rerknimitr, Thawee Ratanachu-ek, Doreen S. C. Koay, Jianyi Calvin Koh, Shiaw-Hooi Ho, Khean-Lee Goh, Sanjiv Mahadeva Diagnostic and Therapeutic Endoscopy.2016; 2016: 1. CrossRef
Cost Comparison between Surgical Treatments and Endoscopic Submucosal Dissection in Patients with Early Gastric Cancer in Korea Younhee Kim, Young-Woo Kim, Il Ju Choi, Joo Young Cho, Jong Hee Kim, Jin-Won Kwon, Ja Youn Lee, Na Rae Lee, Sang-Yong Seol Gut and Liver.2015; 9(2): 174. CrossRef
Evolution of Gastric Cancer Treatment: From the Golden Age of Surgery to an Era of Precision Medicine Yoon Young Choi, Sung Hoon Noh, Jae-Ho Cheong Yonsei Medical Journal.2015; 56(5): 1177. CrossRef
Antifungal Treatment is Not Required for Immunocompetent Individuals With Asymptomatic Esophageal Candidiasis Yang Won Min, Eun Kim, Hee Jung Son, Jae J. Kim, Poong-Lyul Rhee Medicine.2015; 94(45): e1969. CrossRef
Evaluation of transabdominal ultrasound after oral administration of an echoic cellulose-based gastric ultrasound contrast agent for gastric cancer Zhijun Liu, Jintao Guo, Shupeng Wang, Ying Zhao, Jing Li, Weidong Ren, Shaoshan Tang, Limei Xie, Ying Huang, Siyu Sun, Liping Huang BMC Cancer.2015;[Epub] CrossRef
Biopathologic features and clinical significance of micrometatasis in the lymph node of early gastric cancer Min Jung Jo World Journal of Gastroenterology.2015; 21(2): 667. CrossRef
ESD Around the World: United States Norio Fukami Gastrointestinal Endoscopy Clinics of North America.2014; 24(2): 313. CrossRef
Screening of Gastric Cancer: Who, When, and How Jaw–Town Lin Clinical Gastroenterology and Hepatology.2014; 12(1): 135. CrossRef
Endoscopic Resection for Early Gastric Cancer beyond Absolute Indication with Emphasis on Controversial Issues Yang Won Min, Jun Haeng Lee Journal of Gastric Cancer.2014; 14(1): 7. CrossRef
Evaluation of transabdominal ultrasound after oral administration of an echoic cellulose-based gastric ultrasound contrast agent for demonstrating small gastric subepithelial masses Zhijun Liu, Jintao Guo, Siyu Sun, Weidong Ren, Shaoshan Tang, Limei Xie, Liping Huang Abdominal Imaging.2014; 39(2): 424. CrossRef
Implementation of gastric cancer screening – The global experience Mārcis Leja, Weicheng You, M. Constanza Camargo, Hiroshi Saito Best Practice & Research Clinical Gastroenterology.2014; 28(6): 1093. CrossRef
Endoscopic Gastric Cancer Screening and Surveillance in High-Risk Groups Il Ju Choi Clinical Endoscopy.2014; 47(6): 497. CrossRef
Barriers to Cancer Screening among Medical Aid Program Recipients in the Republic of Korea: A Qualitative Study Yoon Young Lee, Jae Kwan Jun, Mina Suh, BoYoung Park, Yeol Kim, Kui Son Choi Asian Pacific Journal of Cancer Prevention.2014; 15(2): 589. CrossRef
D1 versus D2 lymphadenectomy for gastric cancer Benjamin Schmidt, Sam S. Yoon Journal of Surgical Oncology.2013; 107(3): 259. CrossRef
Staging of intestinal‐ and diffuse‐type gastric cancers with theOLGAandOLGIMstaging systems S.‐J. Cho, I. J. Choi, M.‐C. Kook, B.‐H. Nam, C. G. Kim, J. Y. Lee, K. W. Ryu, Y.‐W. Kim Alimentary Pharmacology & Therapeutics.2013; 38(10): 1292. CrossRef
Outcomes and Efficiency of National Gastric Cancer Screening Program in Korea Sang Wook Lee, Beom Jin Kim, Jung Duck Park, Jae Gyu Kim The Korean Journal of Helicobacter and Upper Gastrointestinal Research.2013; 13(2): 95. CrossRef
Cost-effectiveness Outcomes of the National Gastric Cancer Screening Program in South Korea Eun Cho, Moon Hae Kang, Kui Son Choi, MiNa Suh, Jae Kwan Jun, Eun-Cheol Park Asian Pacific Journal of Cancer Prevention.2013; 14(4): 2533. CrossRef
Current evidence of effects ofHelicobacter pylorieradication on prevention of gastric cancer Il Ju Choi The Korean Journal of Internal Medicine.2013; 28(5): 525. CrossRef
Discrimination of gastric cancer from normal by serum RNA based on surface‐enhanced Raman spectroscopy (SERS) and multivariate analysis Yanping Chen, Gang Chen, Xiongwei Zheng, Cheng He, Shangyuan Feng, Yan Chen, Xiaoqian Lin, Rong Chen, Haisan Zeng Medical Physics.2012; 39(9): 5664. CrossRef
Trends in Cancer Screening Rates among Korean Men and Women: Results from the Korean National Cancer Screening Survey (KNCSS), 2004-2011 Boyoung Park, Kui Son Choi, Yoon Young Lee, Jae Kwan Jun, Hong Gwan Seo Cancer Research and Treatment.2012; 44(2): 113. CrossRef
U.S. Geriatricians and Gastric Cancer Screening in Elderly Korean‐American Men: Differences from Korean Geriatricians Chang Won Won, Hwan‐Sik Hwang Journal of the American Geriatrics Society.2012; 60(5): 996. CrossRef
Effectiveness of Interventions to Increase the Participation Rate of Gastric Cancer Screening in the Republic of Korea: a Pilot study Myung-Ha Lee, Yoon-Young Lee, Da-Won Jung, Bo-Young Park, E-Hwa Yun, Hoo-Yeon Lee, Jae-Kwan Jun, Kui-Son Choi Asian Pacific Journal of Cancer Prevention.2012; 13(3): 861. CrossRef
Endoscopist Specialty Is Associated with High-Quality Endoscopy in Korea Jae Myung Cha, Dong Soo Han, Hang Lack Lee, Young Ho Kim, Il-Kwun Chung, Hyun Soo Kim, Jeong Seop Moon, Yu Kyung Cho Yonsei Medical Journal.2012; 53(2): 310. CrossRef
Cancer Screening Status in Korea, 2011: Results from the Korean National Cancer Screening Survey Bo-Young Park, Kui-Son Choi, Yoon-Young Lee, Jae-Kwan Jun, Hong-Gwan Seo Asian Pacific Journal of Cancer Prevention.2012; 13(4): 1187. CrossRef
Current Management and Future Strategies of Gastric Cancer Joong Ho Lee, Kyung Min Kim, Jae-Ho Cheong, Sung Hoon Noh Yonsei Medical Journal.2012; 53(2): 248. CrossRef
Intestinal Metaplasia and the Risk of Gastric Cancer in an Immigrant Asian Population Amir Abadir, Catherine Streutker, Christine Brezden-Masley, Andrea Grin, Young-In Kim Clinical Medicine Insights: Gastroenterology.2012; 5: CGast.S10070. CrossRef
Trends in Cancer Screening Rates among Korean Men and Women: Results from the Korean National Cancer Screening Survey (KNCSS), 2004-2010 Eun-Ha Lee, Hoo-Yeon Lee, Kui Son Choi, Jae Kwan Jun, Eun-Cheol Park, Jin Soo Lee Cancer Research and Treatment.2011; 43(3): 141. CrossRef
Su Jin Lee, Silvia Park, Hee Kyung Ahn, Jun Ho Yi, Eun Yoon Cho, Jong Mu Sun, Jeong Eon Lee, Seok Jin Nam, Jung-Hyun Yang, Yeon Hee Park, Jin Seok Ahn, Young-Hyuck Im
Cancer Res Treat. 2011;43(2):89-95. Published online June 30, 2011
PURPOSE The aim of the current study was to determine the incidence, clinical presentation, and treatment outcomes of "bone-only metastases" in patients with breast cancer and to analyze the impact of hormone receptor (HR) and human epidermal growth factor receptor 2 (HER2) status on prognosis. MATERIALS AND METHODS Between 1994 and 2007, of 968 patients with metastatic breast cancer who underwent palliative management at Samsung Medical Center, 565 (57%) relapsed with distant metastases. Of the 968, 146 (15%) had bone-only metastases during a median follow-up period of 75 months. Among the 146 patients with bone-only metastases, 122 (84%) were relapsed patients after curative surgery and 24 (26%) were initially metastatic cases. RESULTS The median time from primary surgery to bone-only metastases of the 122 patients was 37 months (95% confidence interval [CI], 27 to 46 months). Bone-only metastases were more common in the HR-positive group than in the other subtypes (85% for HR+; 8.2% for HER2+; 6.8% for triple negative. Among all 146 patients, 75 (51%) were treated with hormone therapy. The median post-relapse progression-free survival was 15 months (95%CI, 13 to 17 months). The median overall survival was much longer in the HR+ patients than the HER2+ and triple negative breast cancer patients with marginal statistical significance (65 vs. 40 vs. 40 months, p=0.077). CONCLUSION Breast cancer patients with "bone-only metastases" had excellent clinical outcomes. Further study is now warranted to reveal the underlying biology that regulates the behavior of this indolent tumor, as it should identify 'favorable tumor characteristics' in addition to 'favorable preferential metastatic site.'
Citations
Citations to this article as recorded by
Intersecting Paths: Unraveling the Complex Journey of Cancer to Bone Metastasis Nour Arakil, Shahid Akhtar Akhund, Basant Elaasser, Khalid S. Mohammad Biomedicines.2024; 12(5): 1075. CrossRef
Germacrone alleviates breast cancer‐associated osteolysis by inhibiting osteoclastogenesis via inhibition of MAPK/NF‐κB signaling pathways Zhengjun Lin, Yaocheng Yang, Tang Liu, Ziyi Wu, Xianghong Zhang, Jing Yang Phytotherapy Research.2024; 38(6): 2860. CrossRef
Acro metastasis: A rare presentation in a common cancer Ali Ghanei-Shahmirzadi, Nasrin Namdari, Maral Mokhtari, Pooya Iranpour Current Problems in Cancer: Case Reports.2024; 14: 100292. CrossRef
Concise review: breast cancer stems cells and their role in metastases Mohammad Kamalabadi Farahani, Mohammad Farjadmehr, Amir Atashi, Alireza Momeni, Mahin Behzadifard Annals of Medicine & Surgery.2024; 86(9): 5266. CrossRef
Management of Oligometastatic Breast Cancer: An Expert Committee’s Opinion Dominique Leblanc, Guy Cantin, Alexandra Desnoyers, Jean Dufresne, Giuseppina Laura Masucci, Valérie Panet-Raymond, Éric Poirier, Sara Soldera, Isabelle Gingras Current Oncology.2023; 30(2): 1416. CrossRef
Surgery in the Setting of Metastatic Breast Cancer Jennifer K. Plichta, Mahsa Taskindoust, Rachel A. Greenup Current Breast Cancer Reports.2023; 15(1): 37. CrossRef
Team Approach: Management of Pathologic Fractures Aws Hammad, Osman Ahmed, Philip P. Connell, Daniel Olson, Tessa Balach JBJS Reviews.2023;[Epub] CrossRef
Diagnostic effectiveness of [18F]Fluoroestradiol PET/CT in oestrogen receptor-positive breast cancer: the key role of histopathology. Evidence from an international multicentre prospective study Gianluca Bottoni, Francesco Fiz, Matteo Puntoni, Federica Matteucci, Manuela Monti, Andrea DeCensi, Oriana Nanni, Etienne Brain, Jean Louis Alberini, Bassam Dib, Gianmauro Sacchetti, Pierpaolo Trimboli, Giorgio Treglia, Nadia Harbeck, Simona Sola, Alessan European Journal of Nuclear Medicine and Molecular Imaging.2023; 50(8): 2477. CrossRef
Plasma hPG80 (Circulating Progastrin) as a Novel Prognostic Biomarker for early-stage breast cancer in a breast cancer cohort Alexandre Prieur, Andrew Harper, Momtafin Khan, Bérengère Vire, Dominique Joubert, Léa Payen, Karen Kopciuk BMC Cancer.2023;[Epub] CrossRef
SCUBE2 mediates bone metastasis of luminal breast cancer by modulating immune-suppressive osteoblastic niches Qiuyao Wu, Pu Tian, Dasa He, Zhenchang Jia, Yunfei He, Wenqian Luo, Xianzhe Lv, Yuan Wang, Peiyuan Zhang, Yajun Liang, Wenjin Zhao, Jun Qin, Peng Su, Yi-Zhou Jiang, Zhi-Ming Shao, Qifeng Yang, Guohong Hu Cell Research.2023; 33(6): 464. CrossRef
Abemaciclib, Palbociclib, and Ribociclib in Real-World Data: A Direct Comparison of First-Line Treatment for Endocrine-Receptor-Positive Metastatic Breast Cancer Mónica Cejuela, Ana Gil-Torralvo, M. Ángeles Castilla, M. Ángeles Domínguez-Cejudo, Alejandro Falcón, Marta Benavent, Sonia Molina-Pinelo, Manuel Ruiz-Borrego, Javier Salvador Bofill International Journal of Molecular Sciences.2023; 24(10): 8488. CrossRef
Multidimensional analysis to elucidate the possible mechanism of bone metastasis in breast cancer Kang Yao, Zhu Xiaojun, Zhao Tingxiao, Liao Shiyao, Ji Lichen, Zhang Wei, Li Yanlei, Tian Jinlong, Ding Xiaoyan, Zhang Jun, Bi Qing, Lv Jun BMC Cancer.2023;[Epub] CrossRef
Diagnostic and Prognostic Role of 18F-Fluoroestradiol PET in Metastatic Breast Cancer: The Second Youth of an Older Theranostic Concept Francesco Fiz, Gianluca Bottoni, Giorgio Treglia, Pierpaolo Trimboli, Arnoldo Piccardo Journal of Clinical Medicine.2022; 11(13): 3589. CrossRef
Prominin 1 Significantly Correlated with Bone Metastasis of Breast Cancer and Influenced the Patient’s Prognosis Cheng-cheng Yu, Yi-nan Wu, Kai-min Hu, Su-zhan Zhang, Ali Imran BioMed Research International.2022; 2022: 1. CrossRef
Development of local injectable, bone-targeting nanocarriers of triptolide for treatment of bone-only metastasis Wucheng Wen, Pengbo Guo, Hui Yi Xue, Ho Lun Wong International Journal of Pharmaceutics.2022; 625: 122092. CrossRef
Clinical Characteristics, Prognostic Factors and Treatment Outcomes of Patients with Bone-Only Metastatic Breast Cancer Lina Marie, Dina Braik, Nayef Abdel-Razeq, Hala Abu-Fares, Ahmad Al-Thunaibat, Hikmat Abdel-Razeq Cancer Management and Research.2022; Volume 14: 2519. CrossRef
Bone Metastasis of Breast Cancer: Molecular Mechanisms and Therapeutic Strategies Lulian Pang, Chen Gan, Jian Xu, Yingxue Jia, Jiaying Chai, Runze Huang, Anlong Li, Han Ge, Sheng Yu, Huaidong Cheng Cancers.2022; 14(23): 5727. CrossRef
Is there a role for locoregional treatment of the primary tumor in de novo metastatic breast cancer in the era of tailored therapies? E. Pons-Tostivint, E. Alouani, Y. Kirova, F. Dalenc, C. Vaysse Critical Reviews in Oncology/Hematology.2021; 157: 103146. CrossRef
Leuprorelin combined with letrozole with/without everolimus in ovarian-suppressed premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer: The LEO study Jae Ho Jeong, Jeong Eun Kim, Jin-Hee Ahn, Kyung Hae Jung, Su-Jin Koh, Jaekyung Cheon, Joohyuk Sohn, Gun Min Kim, Keun Seok Lee, Sung Hoon Sim, In Hae Park, Sung-Bae Kim European Journal of Cancer.2021; 144: 341. CrossRef
Analysis of genomics and immune infiltration patterns of epithelial-mesenchymal transition related to metastatic breast cancer to bone Shuzhong Liu, An Song, Yunxiao Wu, Siyuan Yao, Muchuan Wang, Tong Niu, Chengao Gao, Ziquan Li, Xi Zhou, Zhen Huo, Bo Yang, Yong Liu, Yipeng Wang Translational Oncology.2021; 14(2): 100993. CrossRef
Trefoil factor-1 upregulation in estrogen-receptor positive breast cancer correlates with an increased risk of bone metastasis Chiara Spadazzi, Laura Mercatali, Mark Esposito, Yong Wei, Chiara Liverani, Alessandro De Vita, Giacomo Miserocchi, Elisa Carretta, Michele Zanoni, Claudia Cocchi, Alberto Bongiovanni, Federica Recine, Yibin Kang, Toni Ibrahim Bone.2021; 144: 115775. CrossRef
Diagnosis and referral of adults with suspected bony metastases Samantha Downie, Elizabeth Bryden, Fergus Perks, A Hamish RW Simpson BMJ.2021; : n98. CrossRef
Endocrine-Based Treatments in Clinically-Relevant Subgroups of Hormone Receptor-Positive/HER2-Negative Metastatic Breast Cancer: Systematic Review and Meta-Analysis Francesco Schettini, Mario Giuliano, Fabiola Giudici, Benedetta Conte, Pietro De Placido, Sergio Venturini, Carla Rognoni, Angelo Di Leo, Mariavittoria Locci, Guy Jerusalem, Lucia Del Mastro, Fabio Puglisi, PierFranco Conte, Michelino De Laurentiis, Lajos Cancers.2021; 13(6): 1458. CrossRef
Heterogeneity of bone metastases as an important prognostic factor in patients affected by oestrogen receptor-positive breast cancer. The role of combined [18F]Fluoroestradiol PET/CT and [18F]Fluorodeoxyglucose PET/CT Gianluca Bottoni, Arnoldo Piccardo, Francesco Fiz, Giacomo Siri, Federica Matteucci, Andrea Rocca, Oriana Nanni, Manuela Monti, Etienne Brain, Jean Louis Alberini, Bassam Dib, Gian Mauro Sacchetti, Chiara Saggia, Valentina Rossi, Nadia Harbeck, Rachel Wue European Journal of Radiology.2021; 141: 109821. CrossRef
Locoregional therapy in de novo metastatic breast cancer: Systemic review and meta-analysis Daniel Reinhorn, Raz Mutai, Rinat Yerushalmi, Assaf Moore, Eitan Amir, Hadar Goldvaser The Breast.2021; 58: 173. CrossRef
Exosomal miR-19a and IBSP cooperate to induce osteolytic bone metastasis of estrogen receptor-positive breast cancer Kerui Wu, Jiamei Feng, Feng Lyu, Fei Xing, Sambad Sharma, Yin Liu, Shih-Ying Wu, Dan Zhao, Abhishek Tyagi, Ravindra Pramod Deshpande, Xinhong Pei, Marco Gabril Ruiz, Hiroyuki Takahashi, Shunsuke Tsuzuki, Takahiro Kimura, Yin-yuan Mo, Yusuke Shiozawa, Ravi Nature Communications.2021;[Epub] CrossRef
Incidence of Brain Metastases in Nonmetastatic and Metastatic Breast Cancer: Is There a Role for Screening? Adam S. Komorowski, Ellen Warner, Helen J. MacKay, Arjun Sahgal, Kathleen I. Pritchard, Katarzyna J. Jerzak Clinical Breast Cancer.2020; 20(1): e54. CrossRef
Radiation therapy for bone-only metastases in breast cancer patients: A GOCO survey of current clinical practice Marta Bonet, Virginia García, Núria Farré, Manel Algara, Blanca Farrús, Jaume Fernandez, Victoria Reyes, Arancha Eraso, Ana Álvarez, Maria José Cambra, Agustí Pedro, Jordi Vayreda, Claire Lemansky, Françoise Izar, Meritxell Arenas Reports of Practical Oncology & Radiotherapy.2020; 25(1): 113. CrossRef
MicroRNA-429 inhibits bone metastasis in breast cancer by regulating CrkL and MMP-9 Xinxin Zhang, Xiying Yu, Zhenguo Zhao, Zhennan Yuan, Peiqing Ma, Zhibin Ye, Liping Guo, Songfeng Xu, Libin Xu, Ting Liu, Huanmei Liu, Shengji Yu Bone.2020; 130: 115139. CrossRef
Metastatic Presentations of Previously Treated Early-Stage Breast Cancer Patients and Association With Survival Najla Itani, Nicole Grogan, Sarah Mott, Sneha Phadke Clinical Breast Cancer.2020; 20(3): 209. CrossRef
Concordance of real-world versus conventional progression-free survival from a phase 3 trial of endocrine therapy as first-line treatment for metastatic breast cancer Cynthia Huang Bartlett, Jack Mardekian, Matthew James Cotter, Xin Huang, Zhe Zhang, Christina M. Parrinello, Ariel Bulua Bourla, Apar Kishor Ganti PLOS ONE.2020; 15(4): e0227256. CrossRef
International Framework for Red Flags for Potential Serious Spinal Pathologies Laura M. Finucane, Aron Downie, Christopher Mercer, Susan M. Greenhalgh, William G. Boissonnault, Annelies L. Pool-Goudzwaard, Jason M. Beneciuk, Rachel L. Leech, James Selfe Journal of Orthopaedic & Sports Physical Therapy.2020; 50(7): 350. CrossRef
Prognostic Value of Modified IHC4 Score in Patients with Estrogen Receptor-Positive Metastatic Breast Cancer Liang Jin, Kai Chen, Cui Tan, Jianbin Li, Jiayue Luo, Yaping Yang, Yudong Li, Shunying Li, Liling Zhu, Yue Hu, Fengtao Liu, Qiuting You, Min Peng, Zefei Jiang, Qiang Liu The Oncologist.2020; 25(8): e1170. CrossRef
Imaging diagnosis of metastatic breast cancer Filippo Pesapane, Kate Downey, Anna Rotili, Enrico Cassano, Dow-Mu Koh Insights into Imaging.2020;[Epub] CrossRef
Tamoxifen Rechallenge Decreases Metastatic Potential but Increases Cell Viability and Clonogenicity in a Tamoxifen-Mediated Cytotoxicity-Resistant Subline of Human Breast MCF7 Cancer Cells Yung-Chieh Chang, Chun Hei Antonio Cheung, Yao-Lung Kuo Frontiers in Cell and Developmental Biology.2020;[Epub] CrossRef
Treatment effect of palbociclib plus endocrine therapy by prognostic and intrinsic subtype and biomarker analysis in patients with bone-only disease: a joint analysis of PALOMA-2 and PALOMA-3 clinical trials Richard S. Finn, Massimo Cristofanilli, Johannes Ettl, Karen A. Gelmon, Marco Colleoni, Carla Giorgetti, Eric Gauthier, Yuan Liu, Dongrui R. Lu, Zhe Zhang, Cynthia Huang Bartlett, Dennis J. Slamon, Nicholas C. Turner, Hope S. Rugo Breast Cancer Research and Treatment.2020; 184(1): 23. CrossRef
Innovative Options for Bone Metastasis Treatment: An Extensive Analysis on Biomaterials-Based Strategies for Orthopedic Surgeons Ania Naila Guerrieri, Monica Montesi, Simone Sprio, Roberta Laranga, Laura Mercatali, Anna Tampieri, Davide Maria Donati, Enrico Lucarelli Frontiers in Bioengineering and Biotechnology.2020;[Epub] CrossRef
The influence of breast cancer subtype on survival after palliative radiation for osseous metastases Mohamed K. Abdelhakiem, Candice Johnstone, Carmen Bergom, Adam Currey, Jared R. Robbins Cancer Medicine.2020; 9(23): 8979. CrossRef
Racial/ethnic differences in the outcomes of patients with metastatic breast cancer: contributions of demographic, socioeconomic, tumor and metastatic characteristics Jin-Xiao Ren, Yue Gong, Hong Ling, Xin Hu, Zhi-Ming Shao Breast Cancer Research and Treatment.2019; 173(1): 225. CrossRef
Metastatic pattern discriminates survival benefit of primary surgery for de novo stage IV breast cancer: A real-world observational study Kang Wang, Yang Shi, Zhu-Yue Li, Ye-Lei Xiao, Jie Li, Xiang Zhang, Hong-Yuan Li European Journal of Surgical Oncology.2019; 45(8): 1364. CrossRef
The CXCL5/CXCR2 axis is sufficient to promote breast cancer colonization during bone metastasis Ricardo Romero-Moreno, Kimberly J. Curtis, Thomas R. Coughlin, Maria Cristina Miranda-Vergara, Shourik Dutta, Aishwarya Natarajan, Beth A. Facchine, Kristen M. Jackson, Lukas Nystrom, Jun Li, William Kaliney, Glen L. Niebur, Laurie E. Littlepage Nature Communications.2019;[Epub] CrossRef
Single-Agent Oral Vinorelbine as First-Line Chemotherapy for Endocrine-Pretreated Breast Cancer With Bone Metastases and No Visceral Involvement: NORBREAST-228 Phase II Study Guenther G. Steger, Adriana Dominguez, Natalia Dobrovolskaya, Francesco Giotta, Nicole Tubiana-Mathieu, Martin Pecherstorfer, Antonio Ardizzoia, Maria Blasinska-Morawiec, Enrique Espinosa, Gustavo Villanova Clinical Breast Cancer.2018; 18(1): e41. CrossRef
Differential presentation and survival of de novo and recurrent metastatic breast cancer over time: 1990–2010 Judith A. Malmgren, Musa Mayer, Mary K. Atwood, Henry G. Kaplan Breast Cancer Research and Treatment.2018; 167(2): 579. CrossRef
Breast cancer bone metastases: pathogenesis and therapeutic targets Naomi Brook, Emily Brook, Arun Dharmarajan, Crispin R. Dass, Arlene Chan The International Journal of Biochemistry & Cell Biology.2018; 96: 63. CrossRef
Incidence, risk factors and prognostic characteristics of bone metastases and skeletal-related events (SREs) in breast cancer patients: A systematic review of the real world data Hongwei Zhang, Wei Zhu, Ewelina Biskup, Weige Yang, Ziang Yang, Hong Wang, Xiaochun Qiu, Chengjiao Zhang, Guangxia Hu, Guangfu Hu Journal of Bone Oncology.2018; 11: 38. CrossRef
Breast osteoblast-like cells: a new biomarker for the management of breast cancer Manuel Scimeca, Nicoletta Urbano, Rita Bonfiglio, Orazio Schillaci, Elena Bonanno British Journal of Cancer.2018; 119(9): 1129. CrossRef
Post-relapse survival in patients with the early and late distant recurrence in estrogen receptor-positive HER2-negative breast cancer Akiko Ogiya, Kieko Yamazaki, Rie Horii, Tadahiko Shien, Yoshiya Horimoto, Norikazu Masuda, Touko Inao, Mitsuchika Hosoda, Naoko Ishida, Tomofumi Osako, Masato Takahashi, Yumi Endo, Yuichiro Miyoshi, Hiroyuki Yasojima, Nobumoto Tomioka, Hiroko Yamashita Breast Cancer.2017; 24(3): 473. CrossRef
Pattern of metastatic spread and subcategories of breast cancer Catharina Bartmann, Manfred Wischnewsky, Tanja Stüber, Roland Stein, Mathias Krockenberger, Sebastian Häusler, Wolfgang Janni, Rolf Kreienberg, Maria Blettner, Lukas Schwentner, Achim Wöckel, Joachim Diessner Archives of Gynecology and Obstetrics.2017; 295(1): 211. CrossRef
Osteonecrosis of the Jaw in a Breast Cancer Patient Treated with Everolimus and a Single Dose of Zoledronic Acid Claudia Omarini, Maria E. Filieri, Roberta Depenni, Giulia Grizzi, Stefano Cascinu, Federico Piacentini The Breast Journal.2017; 23(5): 610. CrossRef
The critical role of the ZNF217 oncogene in promoting breast cancer metastasis to the bone Aurélie Bellanger, Caterina F Donini, Julie A Vendrell, Jonathan Lavaud, Irma Machuca‐Gayet, Maëva Ruel, Julien Vollaire, Evelyne Grisard, Balázs Győrffy, Ivan Bièche, Olivier Peyruchaud, Jean‐Luc Coll, Isabelle Treilleux, Véronique Maguer‐Satta, Véroniqu The Journal of Pathology.2017; 242(1): 73. CrossRef
Estrogen receptors in breast and bone: from virtue of remodeling to vileness of metastasis I Bado, Z Gugala, S A W Fuqua, X H-F Zhang Oncogene.2017; 36(32): 4527. CrossRef
Which red flags aid the early detection of metastatic bone disease in back pain? Laura Finucane, Susan Greenhalgh, James Selfe Physiotherapy Practice and Research.2017; 38(2): 73. CrossRef
Prognostic utility of FDG PET/CT and bone scintigraphy in breast cancer patients with bone-only metastasis Soyeon Park, Joon-Kee Yoon, Su Jin Lee, Seok Yun Kang, Hyunee Yim, Young-Sil An Medicine.2017; 96(50): e8985. CrossRef
Tolerability of Therapies Recommended for the Treatment of Hormone Receptor-Positive Locally Advanced or Metastatic Breast Cancer Shinji Ohno Clinical Breast Cancer.2016; 16(4): 238. CrossRef
Quality of life and symptom burden in patients with metastatic breast cancer Christine Ecclestone, Ronald Chow, Natalie Pulenzas, Liying Zhang, Angela Leahey, Julia Hamer, Carlo DeAngelis, Gillian Bedard, Rachel McDonald, Anchal Bhatia, Janet Ellis, Eileen Rakovitch, Sherlyn Vuong, Edward Chow, Sunil Verma Supportive Care in Cancer.2016; 24(9): 4035. CrossRef
Evaluation of clinical parameters influencing the development of bone metastasis in breast cancer Joachim Diessner, Manfred Wischnewsky, Tanja Stüber, Roland Stein, Mathias Krockenberger, Sebastian Häusler, Wolfgang Janni, Rolf Kreienberg, Maria Blettner, Lukas Schwentner, Achim Wöckel, Catharina Bartmann BMC Cancer.2016;[Epub] CrossRef
Prolactin receptor in breast cancer: marker for metastatic risk Carrie S Shemanko Journal of Molecular Endocrinology.2016; 57(4): R153. CrossRef
Clinical Characteristics and Outcome of Bone-Only Metastasis in Inflammatory and Noninflammatory Breast Cancers Megumi Kai, Takahiro Kogawa, Diane D. Liu, Tamer M. Fouad, Kazuharu Kai, Naoki Niikura, Limin Hsu, Jie S. Willey, Richard L. Theriault, Vicente Valero, Naoto T. Ueno Clinical Breast Cancer.2015; 15(1): 37. CrossRef
Loading Dose Ibandronate Versus Standard Oral Ibandronate in Patients With Bone Metastases From Breast Cancer Iain R. Macpherson, Caroline Bray, Carol Hopkins, Rosemary A. Hannon, Liz-Anne Lewsley, Diana M. Ritchie, Peter Canney Clinical Breast Cancer.2015; 15(2): 117. CrossRef
Assessing response to treatment of bone metastases from breast cancer: what should be the standard of care? D.K. Woolf, A.R. Padhani, A. Makris Annals of Oncology.2015; 26(6): 1048. CrossRef
Survival time according to the year of recurrence and subtype in recurrent breast cancer Masahiro Nakano, Mamiko Fujisue, Rumiko Tashima, Yasuhiro Okumura, Yasuyuki Nishiyama, Tomofumi Ohsako, Yasuo Toyozumi, Nobuyuki Arima, Reiki Nishimura The Breast.2015; 24(5): 588. CrossRef
Cases of Bone-only Metastasis in Recurrent Breast Cancer Yoko MAEKAWA, Shintaro TAKAO, Koichi HIROKAGA, Mayuko MIKI, Sachiko YOSHIDA Nihon Rinsho Geka Gakkai Zasshi (Journal of Japan Surgical Association).2014; 75(6): 1484. CrossRef
Efficacy of Exemestane in Korean Patients with Metastatic Breast Cancer after Failure of Nonsteroidal Aromatase Inhibitors June Koo Lee, Seock-Ah Im, Daewon Lee, Ji-Yeon Kim, Yoojoo Lim, Eunyoung Lee, Hyeong-Gon Moon, Tae-Yong Kim, Sae-Won Han, Do-Youn Oh, Se-Hoon Lee, Wonshik Han, Dong-Wan Kim, Tae-You Kim, Dong-Young Noh Journal of Breast Cancer.2013; 16(1): 66. CrossRef
Incidence, consequences and treatment of bone metastases in breast cancer patients—Experience from a single cancer centre I. Kuchuk, B. Hutton, P. Moretto, T. Ng, C.L. Addison, M. Clemons Journal of Bone Oncology.2013; 2(4): 137. CrossRef
Zooming in on the schedule of bone-modifying drugs Miguel Martin, Sara López-Tarruella The Lancet Oncology.2013; 14(7): 575. CrossRef
Bone metastases: assessment, management and treatment options Carole Farrell British Journal of Nursing.2013; 22(Sup7): S4. CrossRef
Limites de la scintigraphie osseuse dans le suivi des métastases osseuses du carcinome mammaire : étude du centre tunisien K. Chatti, A. Harrabi, I. Chabchoub, T. Kamoun, R. Sfar, M. Nouira, M.B. Fredj, N. Ayachi, S.B. Ahmed, H. Essabbah Médecine Nucléaire.2012; 36(10): 574. CrossRef
PURPOSE Fluoropyrimidine-based combination chemotherapy, in combination with either oxaliplatin or irinotecan, has demonstrated efficacy and tolerability in treatment of advanced colorectal cancer (ACC). MATERIALS AND METHODS Between January 2006 and December 2007, a total of 478 ACC patients were treated with combination chemotherapy in first-line settings. Combination therapies included: 5-fluorouracil, folinic acid plus oxaliplatin (FOLFOX, n=172), 5-fluorouracil, folinic acid plus irinotecan (FOLFIRI, n=95), capecitabine plus oxaliplatin (XELOX, n=155), and capecitabine plus irinotecan (XELIRI, n=56). FOLFOX and FOLFIRI were repeated every 2 weeks, whereas XELOX and XELIRI were repeated every 3 weeks until occurrence of disease progression or unacceptable toxicity, or until a patient chose to discontinue treatment. RESULTS The median age was 58 years (range, 19 to 84 years) and the median chemotherapy durations for FOLFOX, FOLFIRI, XELOX, and XELIRI were 4.9, 4.5, 5.7, and 5.4 months, respectively. Combination chemotherapy regimens were generally well tolerated. The estimated median progression-free-survival (PFS) for all patients was 6.8 months (95% confidence interval, 6.3 to 7.3 months). No statistically significant difference in PFS was found among regimens used as first-line chemotherapy. Sixty percent (n=290) of patients received second or further lines of therapy after failure. CONCLUSION Fluoropyrimidine-based combination chemotherapy regimens appear to be equally active and tolerable as first-line therapy for ACC.
Citations
Citations to this article as recorded by
Nineteen-year, real-world experience of first-line combination chemotherapy in patients with metastatic colorectal cancer: a propensity score analysis from southern Thailand Jirapat Wonglhow, Chirawadee Sathitruangsak, Arunee Dechaphunkul, Patrapim Sunpaweravong Journal of International Medical Research.2023;[Epub] CrossRef
Polymorphisms in TYMS for Prediction of Capecitabine-Induced Hand-Foot Syndrome in Chinese Patients with Colorectal Cancer Si-Qi Dong, Tong-Min Wang, Jiang-Bo Zhang, Yong-Qiao He, Wen-Qiong Xue, Zi-Yi Wu, Da-Wei Yang, Lian-Jing Cao, Jing-Wen Huang, Xi-Zhao Li, Pei-Fen Zhang, Xiao-Hui Zheng, Wei-Hua Jia Cancer Research and Treatment.2021; 53(3): 724. CrossRef
PURPOSE Hemorrhagic metastatic brain tumors are not rare, but little is known about the surgical outcome following treatment. We conducted this study to determine the result of the surgical outcome of hemorrhagic metastatic brain tumors. MATERIALS AND METHODS From July 2001 to December 2008, 21 patients underwent surgery for hemorrhagic metastatic brain tumors at our institution. 15 patients had lung cancer, 3 had hepatocellular carcinoma, and the rest had rectal cancer, renal cell carcinoma, and sarcoma. 20 patients had macroscopic hemorrhage in the tumors, and one patient had intracerebral hemorrhage surrounding the tumor. A retrospective clinical review was conducted focusing on the patterns of presenting symptoms and signs, as well as local recurrence following surgery. RESULTS Among 21 hemorrhagic brain metastases, local recurrence developed in two patients. The 12 month progression free survival rate was 86.1%. Mean time to progression was 20.8 months and median survival time after surgery was 11.7 months. CONCLUSION The results of our study showed that hemorrhagic metastatic brain tumors rarely recurred after surgery.
Surgery should be considered as a good treatment option for hemorrhagic brain metastasis, especially in cases with increased intracranial pressure or severe neurologic deficits.
Citations
Citations to this article as recorded by
Predictors and surgical outcome of hemorrhagic metastatic brain malignancies Laurèl Rauschenbach, Pia Kolbe, Adrian Engel, Yahya Ahmadipour, Marvin Darkwah Oppong, Alejandro N. Santos, Sied Kebir, Celia Dobersalske, Björn Scheffler, Cornelius Deuschl, Philipp Dammann, Karsten H. Wrede, Ulrich Sure, Ramazan Jabbarli Journal of Neuro-Oncology.2024; 169(1): 165. CrossRef
Should we be afraid of radiotherapy for hemorrhagic brain metastases? A narrative review Aleksandra Łupicka, Weronika Kowalczyk, Bartosz Cyman, Mateusz Spałek Therapeutic Advances in Medical Oncology.2024;[Epub] CrossRef
Hemorrhagic brain metastasis from small-cell carcinoma of the urinary bladder Kazuhide Maeshima, Takahiro Sasaki, Toshikazu Yamoto, Junya Fukai, Hiroki Nishibayashi, Naoyuki Nakao Surgical Neurology International.2022; 13: 20. CrossRef
Hemorrhage in brain tumor – An unresolved issue Robert P. Ostrowski, Zhaohui He, Emanuela B. Pucko, Ewa Matyja Brain Hemorrhages.2022; 3(2): 98. CrossRef
Cardiac Angiosarcomas Andrew J. Bishop, Jing Zheng, Aparna Subramaniam, Amol J. Ghia, Chenyang Wang, Susan L. McGovern, Shreyaskumar Patel, B. Ashleigh Guadagnolo, Devarati Mitra, Ahsan Farooqi, Michael J. Reardon, Betty Kim, Nandita Guha-Thakurta, Jing Li, Vinod Ravi American Journal of Clinical Oncology.2022; 45(6): 258. CrossRef
Correlation Analysis between Retention of Gd-DTPA in the Cystic Area of Brain Metastasis and MRI Signs Jili Wang, Shanshan Qu, Qinyan Xu, Zhaofeng Jin, Tian Li, Shuxian Zhang, Xihe Sun, Qingbin Cui Journal of Oncology.2022; 2022: 1. CrossRef
Efficacy of BRAF Inhibitors in Combination With Stereotactic Radiosurgery for the Treatment of Melanoma Brain Metastases: A Systematic Review and Meta-Analysis Muhammad Khan, Tao Zheng, Zhihong Zhao, Sumbal Arooj, Guixiang Liao Frontiers in Oncology.2021;[Epub] CrossRef
Management of patients suffering from hemorrhagic intracranial metastases: Propositions to help the neurosurgeon in emergency situations based on a literature review S. Boissonneau, T. Graillon, A. Rolland, C. Botella, J. Pallud, H. Dufour Neurochirurgie.2021; 67(4): 369. CrossRef
3D Spatial Distribution of Nanoparticles in Mice Brain Metastases by X-ray Phase-Contrast Tomography Elena Longo, Lucie Sancey, Alessia Cedola, Emmanuel L. Barbier, Alberto Bravin, Francesco Brun, Inna Bukreeva, Michela Fratini, Lorenzo Massimi, Imke Greving, Geraldine Le Duc, Olivier Tillement, Ombeline De La Rochefoucauld, Philippe Zeitoun Frontiers in Oncology.2021;[Epub] CrossRef
Critical cerebellar hemorrhage due to pilocytic astrocytoma in a child: A case report Akihiko Teshigawara, Toshikazu Kimura, Shunsuke Ichi Surgical Neurology International.2021; 12: 448. CrossRef
Preoperative Metastatic Brain Tumor-Associated Intracerebral Hemorrhage Is Associated With Dismal Prognosis Motaz Hamed, Niklas Schäfer, Christian Bode, Valeri Borger, Anna-Laura Potthoff, Lars Eichhorn, Frank A. Giordano, Erdem Güresir, Muriel Heimann, Yon-Dschun Ko, Jennifer Landsberg, Felix Lehmann, Alexander Radbruch, Elisa Scharnböck, Christina Schaub, Kat Frontiers in Oncology.2021;[Epub] CrossRef
Molecular and immunological associations of elevated serum lactate dehydrogenase in metastatic melanoma patients: A fresh look at an old biomarker Grant M. Fischer, Fernando C. L. Carapeto, Aron Y. Joon, Lauren E. Haydu, Huiqin Chen, Fuchenchu Wang, John S. Van Arnam, Jennifer L. McQuade, Khalida Wani, John M. Kirkwood, John F. Thompson, Michael T. Tetzlaff, Alexander J. Lazar, Hussein A. Tawbi, Jef Cancer Medicine.2020; 9(22): 8650. CrossRef
Over-expression of S100B protein as a serum marker of brain metastasis in non-small cell lung cancer and its prognostic value Lijuan Chen, Xiufeng Hu, Huijuan Wu, Yongxu Jia, Jie Liu, Xiaoqian Mu, Hongbo Wu, Yanqiu Zhao Pathology - Research and Practice.2019; 215(3): 427. CrossRef
La radiothérapie en conditions stéréotaxiques des métastases cérébrales en situation complexe G. Noel, A. Keller, D. Antoni Cancer/Radiothérapie.2019; 23(6-7): 708. CrossRef
Multiple massive intratumoral hemorrhages of metastatic brain melanoma after ventriculoperitoneal shunt Tsung-Hsi Yang, Jung-Tung Liu, Fook-How Chan Formosan Journal of Surgery.2019; 52(3): 99. CrossRef
Two Cases of Metastatic Malignant Melanoma Keijiro Hara, Kazuhiro Hirano, Yukari Ogawa, Keita Kinoshita, Satoshi Hirai, Hiroki Takai, Nobuhisa Matsushita, Hiroyuki Toi, Hirotake Nishimura, Ryo Tanaka, Shunji Matsubara, Masaaki Uno Japanese Journal of Neurosurgery.2018; 27(5): 393. CrossRef
Stereotactic radiosurgery for brain metastases from malignant melanoma and the impact of hemorrhagic metastases Kristine Bauer-Nilsen, Daniel M. Trifiletti, Ajay Chatrath, Henry Ruiz-Garcia, Eduardo Marchan, Jennifer Peterson, Byron C. May, Jason P. Sheehan Journal of Neuro-Oncology.2018; 140(1): 83. CrossRef
Posterior Fossa Metastasis–Associated Obstructive Hydrocephalus in Adult Patients: Literature Review and Practical Considerations from the Neuro-Oncology Club of the French Society of Neurosurgery Alexandre Roux, Céline Botella, Megan Still, Marc Zanello, Frédéric Dhermain, Philippe Metellus, Johan Pallud World Neurosurgery.2018; 117: 271. CrossRef
Cerebellar hemorrhage due to dural arteriovenous fistula mimicking a hemorrhagic metastatic brain tumor: a case report Yoichi Yoshida, Yoshinori Higuchi, Ryota Nomura, Shiro Ikegami, Toshimasa Shin, Ayaka Hara, Taiki Setoguchi, Eiichi Kobayashi, Kazuhiro Nomoto, Yasuo Iwadate Nosotchu.2018; 40(6): 427. CrossRef
Risk of Cerebrovascular Events in 178 962 Five-Year Survivors of Cancer Diagnosed at 15 to 39 Years of Age Chloe J. Bright, Mike M. Hawkins, Joyeeta Guha, Katherine E. Henson, David L. Winter, Julie S. Kelly, Richard G. Feltbower, Marlous Hall, David J. Cutter, Angela B. Edgar, Clare Frobisher, Raoul C. Reulen Circulation.2017; 135(13): 1194. CrossRef
Hemorrhage of brain metastasis is a poor prognostic factor in hepatocellular carcinoma patients Yan Lin, Shi-Ting Huang, Yan-Ming Jiang, Xin-Bin Pan Oncotarget.2017; 8(54): 93245. CrossRef
Pointing to the Diagnosis: Hemorrhagic Brain Metastasis Yu-Hsiang Juan, Huei-Fang Hsuan, Yun-Chung Cheung, Shu-Hang Ng, Koon-Kwan Ng, Chin-Wei Yu, Yu-Ying Cheng, Yu-Ching Lin The American Journal of Medicine.2016; 129(12): 1268. CrossRef
Anesthetic Management of Supratentorial Tumors Abirami Kumaresan, Ekkehard Kasper, Ruma Bose International Anesthesiology Clinics.2015; 53(1): 74. CrossRef
Brain Metastasis From Papillary Thyroid Carcinoma in a Seventy-Three-Year-Old Man Babak Alijani, Mohammad Reza Emamhadi, Shahrokh Yousefzadeh Chabok, Hamid Behzadnia, Siavash Dehghani Archives of Neuroscience.2015;[Epub] CrossRef
Post-treatment intracranial hemorrhage of brain metastases from hepatocellular carcinoma Kyung Su Kim, Kyubo Kim, Eui Kyu Chie, Yoon Jun Kim, Jung Hwan Yoon, Hyo-Suk Lee, Sung W. Ha Radiation Oncology Journal.2015; 33(1): 36. CrossRef
Bevacizumab in Patients with Nonsquamous Non–Small Cell Lung Cancer and Asymptomatic, Untreated Brain Metastases (BRAIN): A Nonrandomized, Phase II Study Benjamin Besse, Sylvestre Le Moulec, Julien Mazières, Hélène Senellart, Fabrice Barlesi, Christos Chouaid, Eric Dansin, Henri Bérard, Lionel Falchero, Radj Gervais, Gilles Robinet, Anne-Marie Ruppert, Roland Schott, Hervé Léna, Christelle Clément-Duchêne, Clinical Cancer Research.2015; 21(8): 1896. CrossRef
PURPOSE The genetic alteration of the janus kinases (JAKs), non-receptor tyrosine kinase, is related to the development of human cancers. However, little is known about how the sequence variation of JAK3 contributes to the development of lung cancer. This study investigated whether polymorphisms at the promoter region of the JAK3 gene are associated with the risk of lung cancer in the Korean population. MATERIALS AND METHODS A total of 819 subjects, including 409 lung cancer patients and 410 healthy controls were recruited. The SNaPshot assay and polymerase chain reaction-restriction fragment length polymorphism analysis were used, and logistic regression analyses were performed to characterize the association between polymorphisms of JAK3 and lung cancer risk. RESULTS Three polymorphisms (-672 G>A, +64 A>G and +227 G>A) of JAK3 were analyzed for large-scale genotyping (n=819). Statistical analyses revealed that polymorphisms and haplotypes in the JAK3 gene were not significantly associated with lung cancer. CONCLUSION JAK3 gene was not significantly associated with the risk of lung cancer in the Korean population.
Citations
Citations to this article as recorded by
Association Analysis of Polymorphic Gene Variants in the JAK/STAT Signaling Pathway with Aging and Longevity V. V. Erdman, T. R. Nasibullin, I. A. Tuktarova, R. Sh. Somova, O. E. Mustafina Russian Journal of Genetics.2019; 55(6): 728. CrossRef
PURPOSE To assess the usefulness of adenosine triphosphate-based chemotherapy response assay (ATP-CRA) results in advanced gastric cancer patients receiving adjuvant chemotherapy. MATERIALS AND METHODS Sixty-two patients underwent curative surgical resection between January, 2006 and December, 2008.
Their highly purified surgical specimens were evaluated by ATP-CRAs. Of the 62, 49 had successful assay results and they received either oral 5-fluorouracil or other chemotherapies. We retrospectively analyzed data for 24 patients who were treated with oral 5-fluorouracil and whose assays were successful. RESULTS The median observation time was 24.6 months (range, 10.1 to 40.9 months). The median treatment time was 11.2 months (range, 1.2 to 17.7 months). The median age was 66 years (range, 30 to 81 years). Patients were grouped into sensitive- and resistant-groups according to adenosine triphosphate-based chemotherapy response results for fluorouracil. The sensitive-group showed a significantly longer time to relapse (not reached in the sensitive-group vs. 24.8 months in the resistant-group, p=0.043) and longer overall survival compared to the resistant-group (not reached in the sensitive-group vs. 35.7 months in the resistant-group, p=0.16, statistically insignificant). CONCLUSION Patients who receive curative surgical resection significantly benefit from sensitive adjuvant chemotherapy according to ATP-CRA results for time to relapse.
Citations
Citations to this article as recorded by
In Vitro Adenosine Triphosphate-Based Chemotherapy Response Assay as a Predictor of Clinical Response to Fluorouracil-Based Adjuvant Chemotherapy in Stage II Colorectal Cancer Hye Youn Kwon, Im-kyung Kim, Jeonghyun Kang, Seung-Kook Sohn, Kang Young Lee Cancer Research and Treatment.2016; 48(3): 970. CrossRef
Clinical correlation between <i>in vitro</i> chemoresponse assay and first line chemotherapy for metastatic colorectal cancer patients Sang Hun Jung, So Hyun Kim, Jae Hwang Kim Korean Journal of Clinical Oncology.2015; 11(2): 51. CrossRef
Purinergic signalling in the gastrointestinal tract and related organs in health and disease Geoffrey Burnstock Purinergic Signalling.2014; 10(1): 3. CrossRef
Establishment of 5-fluorouracil-resistant oral squamous cell carcinoma cell lines with epithelial to mesenchymal transition changes KOJI HARADA, TARANNUM FERDOUS, YOSHIYA UEYAMA International Journal of Oncology.2014; 44(4): 1302. CrossRef
Purinergic signalling and cancer Geoffrey Burnstock, Francesco Di Virgilio Purinergic Signalling.2013; 9(4): 491. CrossRef
Establishment and characterization of two 5-fluorouracil-resistant hepatocellular carcinoma cell lines KAZUYA UCHIBORI, ATSUSHI KASAMATSU, MASAHIKO SUNAGA, SATOSHI YOKOTA, TOMOYA SAKURADA, ERIKO KOBAYASHI, MASAHARU YOSHIKAWA, KATSUHIRO UZAWA, SHIRO UEDA, HIDEKI TANZAWA, NOBUNORI SATO International Journal of Oncology.2012; 40(4): 1005. CrossRef
PURPOSE Current chemotherapeutics for treating locally advanced or metastatic soft tissue sarcomas (STS) are limited. Accordingly, the present in vitro study was conducted to evaluate the effects of treatment of STS cells with tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) applied as a single agent or in combination with a proteasome inhibitor, MG132. MATERIALS AND METHODS Sensitivity to TRAIL and activity of TRAIL-induced apoptotic pathways were analyzed in four STS cell lines: HTB-82 (rhabdomyosarcoma), HT-1080 (fibrosarcoma), HTB-93 (synovial sarcoma), and HTB-94 (chondrosarcoma). Reduction of the dye dimethylthiazolyl 2,5 diphenyltetrazolium bromide (MTT) was used to evaluate cytotoxic activity; western blots were used to evaluate TRAIL-induced apoptosis. RESULTS TRAIL induced apoptosis in HTB-93 cells, but had little effect in HTB-82, HT-1080, or HTB-94 cells.
Expression of TRAIL receptor-1 and -2 did not correlate with sensitivity to TRAIL. Co-incubation of cells with TRAIL and a proteasome inhibitor, MG132, augmented the apoptotic effect of TRAIL in both TRAIL-sensitive and TRAIL-resistant cells. This effect was due to up-regulation of TRAIL receptors and members of the pro-apoptotic BCL-2 family by MG132. CONCLUSION These data show that combining TRAIL with MG132 enhances apoptosis and overcomes TRAIL resistance. This restoration of TRAIL sensitivity occurs through an increase in the expression of death receptor 5 and of pro-apoptotic BCL-2 family members such as BAX.
Citations
Citations to this article as recorded by
TRAIL-induced apoptosis and proteasomal activity – Mechanisms, signalling and interplay Chiara Boccellato, Markus Rehm Biochimica et Biophysica Acta (BBA) - Molecular Cell Research.2024; 1871(4): 119688. CrossRef
Advancing the Management of Skull Base Chondrosarcomas: A Systematic Review of Targeted Therapies Edoardo Agosti, Marco Zeppieri, Sara Antonietti, Tamara Ius, Marco Maria Fontanella, Pier Paolo Panciani Journal of Personalized Medicine.2024; 14(3): 261. CrossRef
Proteasome inhibitors as anticancer agents Giorgia Gazzaroli, Andrea Angeli, Arianna Giacomini, Roberto Ronca Expert Opinion on Therapeutic Patents.2023; 33(11): 775. CrossRef
Combination therapy with c-met inhibitor and TRAIL enhances apoptosis in dedifferentiated liposarcoma patient-derived cells Eun Byeol Jo, Young Sang Lee, Hyunjoo Lee, Jae Berm Park, Hyojun Park, Yoon-La Choi, Doopyo Hong, Sung Joo Kim BMC Cancer.2019;[Epub] CrossRef
Disulfide bond-disrupting agents activate the tumor necrosis family-related apoptosis-inducing ligand/death receptor 5 pathway Mengxiong Wang, Mary E. Law, Bradley J. Davis, Elham Yaaghubi, Amanda F. Ghilardi, Renan B. Ferreira, Chi-Wu Chiang, Olga A. Guryanova, Daniel Kopinke, Coy D. Heldermon, Ronald K. Castellano, Brian K. Law Cell Death Discovery.2019;[Epub] CrossRef
The combination of TRAIL and MG-132 induces apoptosis in both TRAIL-sensitive and TRAIL-resistant human follicular lymphoma cells Jemal Adem, Mine Eray, Jonna Eeva, Ulla Nuutinen, Jukka Pelkonen Leukemia Research.2018; 66: 57. CrossRef
Chondrosarcoma: An overview of clinical behavior, molecular mechanisms mediated drug resistance and potential therapeutic targets Elahe Nazeri, Mohammad Gouran Savadkoohi, Keivan Majidzadeh-A, Rezvan Esmaeili Critical Reviews in Oncology/Hematology.2018; 131: 102. CrossRef
TNF-related apoptosis-inducing ligand (TRAIL) for bone sarcoma treatment: Pre-clinical and clinical data Zakareya Gamie, Konstantinos Kapriniotis, Dimitra Papanikolaou, Emma Haagensen, Ricardo Da Conceicao Ribeiro, Kenneth Dalgarno, Anja Krippner-Heidenreich, Craig Gerrand, Eleftherios Tsiridis, Kenneth Samora Rankin Cancer Letters.2017; 409: 66. CrossRef
Activation of TRAIL‐DR5 pathway promotes sensorineural degeneration in the inner ear Shyan‐Yuan Kao, Vitor Y.R. Soares, Arthur G. Kristiansen, Konstantina M. Stankovic Aging Cell.2016; 15(2): 301. CrossRef
Prognostic significance of FOXM1 expression and antitumor effect of FOXM1 inhibition in synovial sarcomas Akira Maekawa, Kenichi Kohashi, Masaaki Kuda, Kunio Iura, Takeaki Ishii, Makoto Endo, Tetsuya Nakatsura, Yukihide Iwamoto, Yoshinao Oda BMC Cancer.2016;[Epub] CrossRef
The Importance of Being Dead: Cell Death Mechanisms Assessment in Anti-Sarcoma Therapy Santiago Rello-Varona, David Herrero-MartÃn, Laura Lagares-Tena, Roser López-Alemany, Núria Mulet-Margalef, Juan Huertas-MartÃnez, Silvia Garcia-Monclús, Xavier GarcÃa del Muro, Cristina Muñoz-Pinedo, Oscar MartÃnez Tirado Frontiers in Oncology.2015;[Epub] CrossRef
Development of a Novel Class of Mitochondrial Ubiquinol–Cytochrome c Reductase Binding Protein (UQCRB) Modulators as Promising Antiangiogenic Leads Hye Jin Jung, Misun Cho, Yonghyo Kim, Gyoonhee Han, Ho Jeong Kwon Journal of Medicinal Chemistry.2014; 57(19): 7990. CrossRef
Mitochondrial UQCRB regulates VEGFR2 signaling in endothelial cells Hye Jin Jung, Yonghyo Kim, Junghwa Chang, Sang Won Kang, Jeong Hun Kim, Ho Jeong Kwon Journal of Molecular Medicine.2013; 91(9): 1117. CrossRef
Cell Death Pathways as Therapeutic Targets in Rhabdomyosarcoma Simone Fulda Sarcoma.2012; 2012: 1. CrossRef
This is a case report about benign metastasizing leiomyoma with multiple lymph node metastasis. A 34-year-old woman received an abdominal myomectomy for a suspicious leiomyoma.
On the pathology report, atypical leiomyoma was suspected.
Due to the suspicion of multiple lymph node metastasis on pelvis computed tomography (CT) 1 year after the operation, she was transferred to the Samsung Medical Center on October, 2009 for further work up. According to original slide review, it was determined to be a benign leiomyoma with a mitotic count <5/10 high-power fields, little cytological atypia and no tumor cell necrosis. Additional immunostaining was done. Multiple lymph node metastasis and a small lung nodule were identified on positron emission tomogarphy-CT and chest CT. Extensive debulking surgery and diagnostic video-assisted thoracoscopic surgery (VATS) wedge resection were subsequently done. Metastatic lesions were reported to have a histology similar to that of the original mass. VATS right upper lobectomy with mediastinal lymph node dissection was performed because of the pathology result of VATS (adenocarcinoma). She started taking an aromatase inhibitor (Letrozole(R)) and there was no evidence of recurrence of disease on an imaging study and no post-operative complications until recently.
Citations
Citations to this article as recorded by
Pulmonary Benign Metastasizing Leiomyoma in a Postmenopausal Woman: A Case Report and Review of the Literature Aleksandra Piórek, Adam Płużański, Piotr Wiśniewski, Sylwia Tabor, Kinga Winiarczyk, Magdalena Knetki-Wróblewska, Dariusz M. Kowalski, Maciej Krzakowski Diseases.2024; 12(8): 181. CrossRef
Benign metastasizing uterine leiomyoma with lymphatic and pulmonary metastases: a case report and literature review Tong Tong, Qiong Fan, Yudong Wang, Yuhong Li BMC Women's Health.2023;[Epub] CrossRef
Pulmonary benign metastasizing uterine leiomyoma (PBML): a case report and review of the literature Mark R. Brincat, Sarah Lam Shang Leen, Asma Faruqi, Michail Sideris, Kelvin Kar Wing Lau, Alexandra Lawrence Annals of Medicine & Surgery.2023; 85(7): 3686. CrossRef
Benign Metastasizing Leiomyoma of the Lung: Diagnostic Process and Treatment Based on Three Case Reports and a Review of the Literature Małgorzata Edyta Wojtyś, Olga Kacalska-Janssen, Konrad Ptaszyński, Piotr Lisowski, Michał Kunc, Janusz Wójcik, Tomasz Grodzki Biomedicines.2022; 10(10): 2465. CrossRef
A case report of atypical uterine leiomyoma Yun Sook Kim, Hyun Joo Lee Medicine: Case Reports and Study Protocols.2021; 3(11): e0168. CrossRef
Metastatic leiomyoma or synchronous lesion of the uteri corpus and vulva? I. V. Barinova, S. N. Buyanova, N. I. Kondrikov, N. A. Shchukina, I. N. Voloshchuk, M. V. Mgeliashvili, S. A. Petrakova, A. A. Aksenova Arkhiv patologii.2020; 82(1): 62. CrossRef
Lung metastases from benign uterine leiomyoma: does 18-FDG-PET/CT have a role to play? Feras Abu Saadeh, Ciaran O. Riain, Ciara Mc Cormack, Noreen Gleeson Irish Journal of Medical Science (1971 -).2019; 188(2): 619. CrossRef
Benign metastasising leiomyoma with lymph node metastases in a patient with endometrial cancer after caesarean section Serra Akar, Serdar Ugras, Gozde Sahin, Fatih Demir, Çetin Çelik Journal of Obstetrics and Gynaecology.2019; 39(3): 420. CrossRef
Benign metastasizing leiomyoma presenting with miliary pattern and fatal outcome: Case report with molecular analysis & review of the literature Kenneth Ofori, Helen Fernandes, Matthew Cummings, Thomas Colby, Anjali Saqi Respiratory Medicine Case Reports.2019; 27: 100831. CrossRef
Gonadotropin-releasing Hormone Agonist Plus Aromatase Inhibitor in the Treatment of Uterine Leiomyoma in Near Menopause Patient: A Case Series Study Sanam Moradan Journal of Menopausal Medicine.2018; 24(1): 62. CrossRef
The Heart as a Site of Metastasis of Benign Metastasizing Leiomyoma: Case Report and Review of the Literature Mariam Meddeb, Robert D. Chow, Randolph Whipps, Reyaz Haque Case Reports in Cardiology.2018; 2018: 1. CrossRef
BENIGN UTERUS CANCER WITH LUNG METASTASES: LEIOMYOMATOSIS, LYMPHANGIOLEIMYOMATOSIS, THORACIC ENDOMETRIOSIS (LITERATURE REVIEW, PERSONAL CLINCIAL OBSERVATIONS) Леншин, Anatoliy Lenshin, Ильин, Andrey Il'in, Демура, Ol'ga Demura, Крайнов, Sergey Kraynov, Побережский, Aleksey Poberezhskiy Bulletin physiology and pathology of respiration .2017; : 30. CrossRef
Benign metastasizing leiomyoma and 18-FDG-PET/CT: A case report and literature review Yusuke Sawai, Toshiki Shimizu, Yuta Yamanaka, Maiko Niki, Shosaku Nomura Oncology Letters.2017; 14(3): 3641. CrossRef
Mesothelial cell deposits in lymph nodes—a diagnostic pitfall Archana Pandita, Vladimir Osipov Annals of Diagnostic Pathology.2016; 25: 31. CrossRef
Recommendations and Technical Aspects of 16α-[18F]Fluoro-17β-Estradiol PET to Image the Estrogen Receptor In Vivo Clasina M. Venema, Giulia Apollonio, Geke A.P. Hospers, Carolina P. Schröder, Rudi A.J.O. Dierckx, Erik F.J. de Vries, Andor W.J.M. Glaudemans Clinical Nuclear Medicine.2016; 41(11): 844. CrossRef
Single benign metastasising leiomyoma of an inguinal lymph node Kamil G Laban, Roberto E Tobon-Morales, Janice A L Hodge, Henk W R Schreuder BMJ Case Reports.2016; : bcr2016216546. CrossRef
Leiomyomas beyond the uterus; benign metastasizing leiomyomatosis with paraaortic metastasizing endometriosis and intravenous leiomyomatosis: a case series and review of the literature Mohamad S. Mahmoud, Kavita Desai, Farr R. Nezhat Archives of Gynecology and Obstetrics.2015; 291(1): 223. CrossRef
Benign pulmonary metastasizing leiomyoma of the uterus: A case report HUI MA, JIE CAO Oncology Letters.2015; 9(3): 1347. CrossRef
Single-port laparoscopic debulking surgery of variant benign metastatic leiomyomatosis with simultaneous lymphatic spreading and intraperitoneal seeding Yoo Hyun Chung, Suk Woo Lee, So Young Shin, Chae Chun Rhim, Soyoung Im, Sie Hyeon Yoo, Joo Hee Yoon Obstetrics & Gynecology Science.2015; 58(4): 314. CrossRef
Benign metastasizing leiomyoma of the lung: A case report and literature review WEI-TIAN WEI, PENG-CHENG CHEN Oncology Letters.2015; 10(1): 307. CrossRef
Difficulty in complete transarterial embolization for pulmonary benign metastasizing leiomyoma with massive hemoptysis Masaya Miyazaki, Akie Nakayama, Daichi Noda, Yasunobu Maehara, Yoshito Tsushima Japanese Journal of Radiology.2014; 32(1): 53. CrossRef
Pulmonary leiomyomas in a patient with bilateral renal cell cancer mimicking pulmonary metastases Ying-Yi Chen, Seng-Tang Wu, Hsian-Her Hsu, Ya-Cheng Chen, Shih-Chun Lee, Hung Chang, Tsai-Wang Huang Clinical Imaging.2014; 38(3): 330. CrossRef
Incidental Benign Metastasizing Leiomyoma in a Patient with Bone Sarcoma: A Case Report Zanndor Jacob del Real-Romo, Carlos Montero-Cantú, Oscar Villegas-Cabello, José Antonio Díaz-Elizondo, Danae Reyes-Salas, Rene Palomo-Hoil, Guillermo Peralta-Castillo, David Martínez-Sánchez, Eduardo Flores-Villalba Case Reports in Surgery.2014; 2014: 1. CrossRef
Metastasizing Leiomyoma to Heart Erin N. Consamus, Michael J. Reardon, Alberto G. Ayala, Mary R. Schwartz, Jae Y. Ro Methodist DeBakey Cardiovascular Journal.2014; 10(4): 251. CrossRef
METASTASISING LEIOMYOMA- A CASE REPORT Krishna Govindan, Sheela Kuzhiveli Mohammed Ali, Lekshmy Kausthubham Sudheendran Journal of Evolution of Medical and Dental Sciences.2014; 7(42): 4591. CrossRef
Benign Metastatic Leiomyoma Presenting as a Hemothorax Anna M. Ponea, Creticus P. Marak, Harmeen Goraya, Achuta K. Guddati Case Reports in Oncological Medicine.2013; 2013: 1. CrossRef
Novel hormone treatment of benign metastasizing leiomyoma: an analysis of five cases and literature review Erin I. Lewis, Rebecca J. Chason, Alan H. DeCherney, Alicia Armstrong, John Elkas, Aradhana M. Venkatesan Fertility and Sterility.2013; 99(7): 2017. CrossRef
Sex-specific lung diseases: effect of oestrogen on cultured cells and in animal models Bosung Shim, Gustavo Pacheco-Rodriguez, Jiro Kato, Thomas N. Darling, Martha Vaughan, Joel Moss European Respiratory Review.2013; 22(129): 302. CrossRef
Pulmonary benign metastasizing leiomyoma: a case report and review of the literature Yili Fu, Hui Li, Bo Tian, Bin Hu World Journal of Surgical Oncology.2012;[Epub] CrossRef
Painful ophthalmoplegia (PO) and concomitant numb chin syndrome (NCS) is a very rare event. There are a few reports in the literature about PO and concomitant NCS that have preceded the diagnosis of a malignancy. In this report, we describe a patient with diffuse large B cell lymphoma who presented with PO and concomitant NCS as the initial symptom of the disease.
Citations
Citations to this article as recorded by
Numb chin syndrome Cristina Perez, Reny de Leeuw, Francisco Escala P., Rodrigo Fuentealba, Gary D. Klasser The Journal of the American Dental Association.2023; 154(1): 79. CrossRef
Numb chin syndrome in sickle cell disease: a case series of Jamaican patients Zachary Ramsay, Christine Hammond Gabbadon, Monika Asnani Annals of Hematology.2021; 100(4): 913. CrossRef
A case of paresthesia of the contralateral mental region suspected to be an early symptom of diffuse large B-cell lymphoma Daiki TAKAHASHI, Masaya AKASHI, Yusuke TAKAHASHI, Kazuyuki TSUJI, Tsutomu MINAMIKAWA, Takahide KOMORI Japanese Journal of Oral and Maxillofacial Surgery.2016; 62(4): 163. CrossRef
Síndrome del mentón entumecido como manifestación de recidiva tumoral M. García-Lamazares, O. Ferreiro-Uriz, L. Alfaya-García SEMERGEN - Medicina de Familia.2014; 40(2): e43. CrossRef
Primary Retroperitoneal Diffuse Large B-cell Lymphoma Presenting with Numb Chin Syndrome and Painful Ophthalmoplegia Satoshi Ichikawa, Kei Saito, Takuma Suzuki, Jun Kimura, Hideo Harigae Internal Medicine.2013; 52(16): 1813. CrossRef